Search

Your search keyword '"D'Arminio Monforte A"' showing total 462 results

Search Constraints

Start Over You searched for: Author "D'Arminio Monforte A" Remove constraint Author: "D'Arminio Monforte A" Language undetermined Remove constraint Language: undetermined
462 results on '"D'Arminio Monforte A"'

Search Results

1. Real world efficacy of dolutegravir plus lamivudine in people living with HIV with undetectable viral load after previous failures

5. HIV-1 drug resistance in people on dolutegravir-based ART: Collaborative analysis of cohort studies

6. Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy

7. Awareness and perception of accuracy of the Undetectable=Untransmittable message (U=U) in Italy: results from a survey among PLWHA, infectious-diseases physicians and people having unprotected sex

8. One‐year cognitive follow‐up of COVID‐19 hospitalized patients

9. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process

10. Incidence of dyslipidemia in people with HIV who are treated with integrase inhibitors versus other antiretroviral agents

11. Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

12. An explainable model of host genetic interactions linked to COVID-19 severity

13. Prevalence and Outcomes for Heavily Treatment-Experienced Individuals Living With Human Immunodeficiency Virus in a European Cohort

14. Association of Toll-like receptor 7 variants with life-threatening COVID-19 disease in males: findings from a nested case-control study

15. Prevalence and outcomes of pregnancies in women with HIV over a 20-year period

16. The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study

17. Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study

18. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

19. Time spent with HIV-RNA ≤ 200 copies/ml in a cohort of people with HIV during the U=U era

20. Long-term positive effect of an educational antimicrobial stewardship program implemented in an Internal Medicine Department: a prospective analysis and a point prevalence survey on long-term effect

21. A Multicenter Phase 2 Randomized Controlled Study on the Efficacy and Safety of Reparixin in the Treatment of Hospitalized Patients with COVID-19 Pneumonia

23. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients

24. MO409: GDF-15 is a Predictor of Mortality in Chronic Kidney Disease Patients With Covid-19 Infection

25. Real World Estimate of Vaccination Protection in Individuals Hospitalized for COVID-19

26. Compassionate Use of Remdesivir for Patients with Severe Covid-19

27. Decrease in Incidence Rate of Hospitalizations Due to AIDS-Defining Conditions but Not to Non-AIDS Conditions in PLWHIV on cART in 2008-2018 in Italy

28. Human Immunodeficiency Virus Continuum of Care in 11 European Union Countries at the End of 2016 Overall and by Key Population: Have We Made Progress?

29. Is the rate of virological failure to cART continuing to decline in recent calendar years?

30. Anxiety and depression symptoms after virological clearance of COVID‐19: A cross‐sectional study in Milan, Italy

31. Effectiveness of Switching to Darunavir/Cobicistat in Virologically Suppressed HIV-Positive Patients Receiving Ritonavir-Boosted Protease Inhibitor–Based Regimen: The 'STORE' Study

32. Renal safety in 3264 HCV patients treated with DAA-based regimens: Results from a large Italian real-life study

33. Switching from efavirenz to rilpivirine improves sleep quality and self-perceived cognition but has no impact on neurocognitive performances

34. Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

35. Sarilumab Plus Standard of Care Versus Standard of Care for the Treatment of Severe COVID-19: A Phase 3, Randomized, Open-Labeled, Multi-Center Study (ESCAPE Study)

36. Parameter estimates for trends and patterns of excess mortality among persons on antiretroviral therapy in high-income European settings

37. Reorienting health systems to care for people with HIV beyond viral suppression

38. In the setting of HIV-infection, HBV-reactivation is revealed by highly sensitive assays in a conspicuous fraction of anti-HBc-positive/HBsAg-negative patients switching to Tenofovir-sparing therapy

39. Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium

40. Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART

41. Neurology of COVID-19

42. Persistence of High Percentage of Peripheral Activated CD8+ T Cells Predict Cytologic HPV-Related Dysplasia in cART-Treated, HIV-Positive Subjects

44. Management of Chronic Hepatitis B in HIV-Coinfected Patients

46. Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy

47. Prevalence of Chagas disease and strongyloidiasis among HIV-infected Latin American immigrants in Italy - The CHILI study

48. Incidence, Risk Factors and Impact on Clinical Outcomes of Bloodstream Infections in Patients Hospitalised with COVID-19: A Prospective Cohort Study

49. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL

50. SARS-CoV-2 susceptibility and COVID-19 disease severity are associated with genetic variants affecting gene expression in a variety of tissues

Catalog

Books, media, physical & digital resources